PMC8320332_01
Periodic acid-Schiff staining of bone marrow aspirate from the 3 patients at the time of admission. (A) Patient 1 had acute myeloid leukemia, (B) Patient 2 had chronic myeloid leukemia, and (C) Patient 3 had acute myeloid leukemia. (D) Patient 3 experienced complete remission after the chemotherapy.
fonc-11-628927-g001.jpg
PMC8320332_03_fonc-11-628927-g001.jpg
f1
A substantial leukocyte abnormality was detected during the treatment period, and a diagnosis of AML was made on the basis of bone marrow aspirate examination ( Figure 1C ). Surprisingly, the subdural hematoma was significantly absorbed after completion of chemotherapy ( Figures 4C, D ) and the patient's symptoms disappeared with complete remission of the AML ( Figure 1D ).
Neuroimaging findings for Patient 1. (A) Chronic subdural hematoma (red arrows) was detected in the bilateral frontotemporal lobes after head trauma. (B) After 4 weeks of atorvastatin treatment, the left-side hematoma was slightly absorbed. (C, D) Absorption of the hematoma after 8 weeks and 12 weeks of conservative treatment using atorvastatin plus low-dose dexamethasone.
fonc-11-628927-g002.jpg
PMC8320332_01_fonc-11-628927-g002.jpg
f2
One month later, the patient developed headache and confusion, and bilateral CSDH was detected during head computed tomography (CT) ( Figure 2A ). Treatment was immediately started using atorvastatin (20 mg/day), the patient's symptoms were significantly relieved after 4 weeks, and magnetic resonance imaging (MRI) revealed slight absorption of the left-side hematoma ( Figure 2B ). Low-dose dexamethasone was added to the conservative treatment at 4 weeks, and CT at the 8-week follow-up revealed substantial absorption of the CSDH ( Figure 2C ). The dexamethasone treatment was subsequently stopped, but atorvastatin treatment was continued until week 12, at which point CT revealed that the hematoma had nearly disappeared ( Figure 2D ).
PMC8320332_02
Periodic acid-Schiff staining of bone marrow aspirate from the 3 patients at the time of admission. (A) Patient 1 had acute myeloid leukemia, (B) Patient 2 had chronic myeloid leukemia, and (C) Patient 3 had acute myeloid leukemia. (D) Patient 3 experienced complete remission after the chemotherapy.
fonc-11-628927-g001.jpg
PMC8320332_03_fonc-11-628927-g001.jpg
f1
A substantial leukocyte abnormality was detected during the treatment period, and a diagnosis of AML was made on the basis of bone marrow aspirate examination ( Figure 1C ). Surprisingly, the subdural hematoma was significantly absorbed after completion of chemotherapy ( Figures 4C, D ) and the patient's symptoms disappeared with complete remission of the AML ( Figure 1D ).
Neuroimaging findings for Patient 2. (A) A 72-year-old man with chronic myeloid leukemia was diagnosed as having right frontotemporal chronic subdural hematoma (red arrow). (B) The hematoma was significantly absorbed after 2 weeks of conservative treatment. (C) New bleeding in the subdural space was detected via magnetic resonance imaging at the 4-week follow-up. (D) Obvious absorption was observed after 10 weeks and (E) near disappearance was observed after 20 weeks of conservative treatment.
fonc-11-628927-g003.jpg
PMC8320332_02_fonc-11-628927-g003.jpg
f3
The patient developed CSDH after experiencing head trauma, which resulted in dizziness, headache, and left-limb weakness ( Figure 3A ). After 2 weeks of conservative treatment using atorvastatin plus dexamethasone, the hematoma was substantially absorbed, and the patient's symptoms were significantly relieved ( Figure 3B ). However, the patient's symptoms worsened during the 4th week of treatment, at which point head MRI revealed new bleeding in the subdural space ( Figure 3C ). At 10 weeks, CT revealed that the hematoma had been significantly absorbed ( Figure 3D ), and the hematoma gradually disappeared during the 5-month follow-up, with complete relief of the patient's symptoms ( Figure 3E ).
PMC8320332_03
Periodic acid-Schiff staining of bone marrow aspirate from the 3 patients at the time of admission. (A) Patient 1 had acute myeloid leukemia, (B) Patient 2 had chronic myeloid leukemia, and (C) Patient 3 had acute myeloid leukemia. (D) Patient 3 experienced complete remission after the chemotherapy.
fonc-11-628927-g001.jpg
PMC8320332_03_fonc-11-628927-g001.jpg
f1
A substantial leukocyte abnormality was detected during the treatment period, and a diagnosis of AML was made on the basis of bone marrow aspirate examination ( Figure 1C ). Surprisingly, the subdural hematoma was significantly absorbed after completion of chemotherapy ( Figures 4C, D ) and the patient's symptoms disappeared with complete remission of the AML ( Figure 1D ).
Neuroimaging findings for Patient 3. (A) Computed tomography revealed bilateral chronic subdural hematoma (red arrows). (B) After 2 weeks of atorvastatin treatment plus low-dose dexamethasone, magnetic resonance imaging revealed an increase in the hematoma, with significant enhancement of the dura mater (green arrows) post-injection of contrast agent. (C, D) After chemotherapy, subdural mass was significantly absorbed in 8-14 weeks. (E) A 5 months follow-up MRI exhibited no hematoma in the subdural space.
fonc-11-628927-g004.jpg
PMC8320332_03_fonc-11-628927-g004.jpg
f4
A 68-year-old man with a 1-month history of headache and dizziness was diagnosed as having CSDH ( Figure 4A ). After 2 weeks of inpatient therapy, head MRI revealed that the subdural mass had grown, with significant enhancement of the dura mater ( Figure 4B ). Surprisingly, the subdural hematoma was significantly absorbed after completion of chemotherapy ( Figures 4C, D ) and the patient's symptoms disappeared with complete remission of the AML ( Figure 1D ). The 5-month follow-up MRI findings ( Figure 4E ) revealed no subdural hematoma and the patient did not experience any severe side effects during the treatment period.